John Flavin
Contributor
More posts by this contributor
2021 should be a banner year for biotech startups that make smart choices early
Kevin O’Connor
Contributor
Kevin A. O’Connor, Ph.D., is a partner in the Intellectual Property practice group at Neal Gerber Eisenberg.
After a record year for biotech investment in 2020 — during which the industry saw $28.5 billion invested across 1,073 deals — the market for new innovations remains strong. What’s more, these innovations are increasingly coming to market by way of early-stage startups and/or their scientific founders from academia.
In 2018, for instance, U.S. campuses conducted $79 billion worth of sponsored …
